A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3658 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3658-3658

Author(s):

T. H. Cartwright ◽

T. Lopez ◽

S. J. Vukelja ◽

C. Encarnacion ◽

K. A. Boehm ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

Open Label Study ◽

Label Study ◽

First Line Treatment

Download Full-text

Results of a Phase II Open-Label Study of Capecitabine in Combination with Irinotecan as First-Line Treatment for Metastatic Colorectal Cancer

Clinical Colorectal Cancer ◽

10.3816/ccc.2005.n.016 ◽

2005 ◽

Vol 5 (1) ◽

pp. 50-56 ◽

Author(s):

Thomas Cartwright ◽

Timothy Lopez ◽

Svetislava J. Vukelja ◽

Carlos Encarnacion ◽

Kristi A. Boehm ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

Open Label Study ◽

Label Study ◽

First Line Treatment

Download Full-text

A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3658 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3658-3658 ◽

Author(s):

T. H. Cartwright ◽

T. Lopez ◽

S. J. Vukelja ◽

C. Encarnacion ◽

K. A. Boehm ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

Open Label Study ◽

Label Study ◽

First Line Treatment

Download Full-text

Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3596 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3596-3596 ◽

Author(s):

M. Ducreux ◽

A. Adenis ◽

J. Bennouna ◽

T. Conroy ◽

R. Faroux ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Safety Analysis ◽

Phase Iii ◽

Line Treatment ◽

Open Label Study ◽

Label Study ◽

First Line Treatment

Download Full-text

O-0024 Phase 2 Randomized, Noncomparative, Open-Label Study of Aflibercept and Modified Folfox6 in the First-Line Treatment of Metastatic Colorectal Cancer (AFFIRM)

Annals of Oncology ◽

10.1016/s0923-7534(19)66488-4 ◽

2012 ◽

Vol 23 ◽

pp. iv16 ◽

Author(s):

Carles Pericay ◽

Gunnar Folprecht ◽

Mark Saunders ◽

Anne Thomas ◽

Jae Kyung Roh ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Line Treatment ◽

Phase 2 ◽

Open Label Study ◽

Label Study ◽

Modified Folfox6 ◽

First Line Treatment

Download Full-text

An open-label phase II study of intermittent oral capecitabine (X) as first-line treatment for patients (pts) with metastatic colorectal cancer (MCRC)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3730 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3730-3730

Author(s):

G. Zhongzhen ◽

F. Fengyi ◽

L. Xiaoqing ◽

W. Yajie ◽

Y. Baoming ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Oral Capecitabine ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Phase II open-label study of weekly taxoprexin (TXP) as first-line treatment in patients with metastatic cutaneous and mucosal malignant melanoma

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.9056 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 9056-9056 ◽

Author(s):

J. Homsi ◽

A. Y. Bedikian ◽

K. B. Kim ◽

N. E. Papadopoulos ◽

W. Hwu ◽

...

Keyword(s):

Malignant Melanoma ◽

Phase Ii ◽

Line Treatment ◽

Open Label Study ◽

Label Study ◽

Mucosal Malignant Melanoma ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717997102.793478384 ◽

2013 ◽

Author(s):

Sabine Tejpar ◽

Loredana Vecchione

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

Wild Type ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study

Annals of Oncology ◽

10.1093/annonc/mdt116 ◽

2013 ◽

Vol 24 (7) ◽

pp. 1769-1777 ◽

Author(s):

T. Brodowicz ◽

T.E. Ciuleanu ◽

D. Radosavljevic ◽

E. Shacham-Shmueli ◽

D. Vrbanec ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

Wild Type ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text